Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06618196
PHASE2

Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

Sponsor: LG Chem

View on ClinicalTrials.gov

Summary

This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.

Official title: A Phase II, Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Immunogenicity and Safety of DTaP-HepB-IPV-Hib Hexavalent Vaccine LR20062 Versus Hexaxim Administered Intramuscularly in Healthy Infants As Primary Series At 2, 4, 6 Months of Age

Key Details

Gender

All

Age Range

50 Days - 70 Days

Study Type

INTERVENTIONAL

Enrollment

336

Start Date

2024-10-02

Completion Date

2026-04-30

Last Updated

2024-10-01

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

LR20062

DTaP-HepB-IPV-Hib vaccine

BIOLOGICAL

DTaP-HepB-IPV-Hib vaccine

Control hexavalent vaccine